Albumin-based potential drugs: focus on half-life extension and nanoparticle preparation

Journal of Pharmaceutical Investigation

Volumn 46, Issue 4, 2016, Pages 305-315

  Lee, Eun Seong ^a   Youn, Yu Seok ^b  

^a The Catholic University of Korea   (South Korea)

^b Sungkyunkwan University   (South Korea)

Author keywords

Albumin; Cancer; Diabetes; Half life extension; Nanoparticles; Targeting

Indexed keywords

10 HYDROXYCAMPTOTHECIN; ALBIGLUTIDE; ARTEMISININ; BONE MORPHOGENETIC PROTEIN 2; CURCUMIN; DOCETAXEL; DOXORUBICIN; GABAPENTIN; HUMAN SERUM ALBUMIN; INSULIN DEGLUDEC; INSULIN DETEMIR; ITRACONAZOLE; LIRAGLUTIDE; LOPERAMIDE; NANOPARTICLE; PACLITAXEL; PILOCARPINE; RAPAMYCIN; SEMAGLUTIDE; TACROLIMUS; TAMOXIFEN; TENIPOSIDE;

BINDING AFFINITY; COACERVATION; HALF LIFE TIME; HUMAN; MOLECULARLY TARGETED THERAPY; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW; ZETA POTENTIAL;

EID: 84978933450     PISSN: 20935552     EISSN: 20936214     Source Type: Journal    
DOI: 10.1007/s40005-016-0250-3     Document Type: Review

References (60)

1. Bae S, Ma K, Kim TH, Lee ES, Oh KT, Park ES, Lee KC, Youn YS (2012) Doxorubicin–loaded human serum albumin nanoparticles surface–modified with TNF–related apoptosis–inducing ligand and transferrin for targeting multiple tumor types. Biomaterials 33(5):1536–1546
2. Baggio LL, Huang Q, Cao X, Drucker DJ (2008) An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis. Gastroenterology 134(4):1137–1147
3. Ballantyne FC, Fleck A, Dick WC (1971) Albumin metabolism in rheumatoid arthritis. Ann Rheum Dis 30(3):265–270
4. Battogtokh G, Kang JH, Ko YT (2015) Long-circulating self-assembled cholesteryl albumin nanoparticles enhance tumor accumulation of hydrophobic anticancer drug. Eur J Pharm Biopharm 96:96–105
5. Bosse D, Praus M, Kiessling P, Nyman L, Andresen C, Waters J, Schindel F (2005) Phase I comparability of recombinant human albumin and human serum albumin. J Clin Pharmacol 45(1):57–67
6. Byeon HJ, Min SY, Kim I, Lee ES, Oh KT, Shin BS, Lee KC, Youn YS (2014) Human serum albumin-TRAIL conjugate for the treatment of rheumatoid arthritis. Bioconjug Chem 25(12):2212–2221
7. Byeon HJ, le Thao Q, Lee S, Min SY, Lee ES, Shin BS, Choi HG, Youn YS (2016) Doxorubicin-loaded nanoparticles consisted of cationic- and mannose-modified-albumins for dual-targeting in brain tumors. J Control Release 225:301–313
8. Chae SY, Choi YG, Son S, Jung SY, Lee DS, Lee KC (2010) The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics. J Control Release 144(1):10–16
9. Chen W, Gu B, Wang H, Pan J, Hou H (2008) Development and evaluation of novel itraconazole-loaded intravenous nanoparticles. Int J Pharm 362(1–2):133–140
10. Choi SH, Byeon HJ, Choi JS, Thao L, Kim I, Lee ES, Shin BS, Lee KC, Youn YS (2015) Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer. J Control Release 197:199–207
11. Chuang VT, Kragh-Hansen U, Otagiri M (2002) Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm Res 19(5):569–577
12. Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, Tao C, De T, Beals B, Dykes D, Noker P, Yao R, Labao E, Hawkins M, Soon-Shiong P (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI–007, compared with cremophor–based paclitaxel. Clin Cancer Res 12(4):1317–1324
13. Dreis S, Rothweiler F, Michaelis M, Cinatl J Jr, Kreuter J, Langer K (2007) Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles. Int J Pharm 341(1–2):207–214
14. Elsadek B, Kratz F (2012) Impact of albumin on drug delivery—new applications on the horizon. J Control Release 157(1):4–28
15. Gong J, Huo M, Zhou J, Zhang Y, Peng X, Yu D, Zhang H, Li J (2009) Synthesis, characterization, drug-loading capacity and safety of novel octyl modified serum albumin micelles. Int J Pharm 376(1–2):161–168
16. He X, Xiang N, Zhang J, Zhou J, Fu Y, Gong T, Zhang Z (2015) Encapsulation of teniposide into albumin nanoparticles with greatly lowered toxicity and enhanced antitumor activity. Int J Pharm 487(1–2):250–259
17. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, Jain RK (1998) Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA 95(8):4607–4612
18. Ibrahim N, Ibrahim H, Dormoi J, Briolant S, Pradines B, Moreno A, Mazier D, Legrand P, Nepveu F (2014) Albumin-bound nanoparticles of practically water–insoluble antimalarial lead greatly enhance its efficacy. Int J Pharm 464(1–2):214–224
19. Ibrahim N, Ibrahim H, Sabater AM, Mazier D, Valentin A, Nepveu F (2015) Artemisinin nanoformulation suitable for intravenous injection: preparation, characterization and antimalarial activities. Int J Pharm 495(2):671–679
20. Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agersø H, Veldhuis J, Pørksen N, Schmitz O (2002) Bedtime administration of NN2211, a long–acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 51(2):424–429
21. Kim JG, Baggio LL, Bridon DP, Castaigne JP, Robitaille MF, Jetté L, Benquet C, Drucker DJ (2003) Development and characterization of a glucagon–like peptide 1-albumin conjugate: the ability to activate the glucagon–like peptide 1 receptor in vivo. Diabetes 52(3):751–759
22. Kim I, Kim TH, Ma K, Lee ES, Kim D, Oh KT, Lee DH, Lee KC, Youn YS (2010) Synthesis and evaluation of human serum albumin-modified exendin-4 conjugate via heterobifunctional polyethylene glycol linkage with protracted hypoglycemic efficacy. Bioconjug Chem 21(8):1513–1519
23. Kim H, Park H, Lee J, Kim TH, Lee ES, Oh KT, Lee KC, Youn YS (2011a) Highly porous large poly(lactic-co-glycolic acid) microspheres adsorbed with palmityl-acylated exendin-4 as a long–acting inhalation system for treating diabetes. Biomaterials 32(6):1685–1693
24. Kim TH, Jiang HH, Youn YS, Park CW, Lim SM, Jin CH, Tak KK, Lee HS, Lee KC (2011b) Preparation and characterization of Apo2L/TNF-related apoptosis-inducing ligand-loaded human serum albumin nanoparticles with improved stability and tumor distribution. J Pharm Sci 100(2):482–491
25. Kim TH, Jiang HH, Youn YS, Park CW, Tak KK, Lee S, Kim H, Jon S, Chen X, Lee KC (2011c) Preparation and characterization of water-soluble albumin–bound curcumin nanoparticles with improved antitumor activity. Int J Pharm 403(1–2):285–291
26. Kim I, Choi JS, Lee S, Byeon HJ, Lee ES, Shin BS, Choi HG, Lee KC, Youn YS (2015) In situ facile-forming PEG cross-linked albumin hydrogels loaded with an apoptotic TRAIL protein. J Control Release 214:30–39
27. Kouchakzadeha O, Shojaosadatia SA, Shokrib F (2014) Efficient loading and entrapment of tamoxifen in human serum albumin based nanoparticulate delivery system by a modified desolvation technique. Chem Eng Res Des 92:1681–1692
28. Kratz F (2008) Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 132(3):171–183
29. Kurtzhals P, Havelund S, Jonassen I, Markussen J (1997) Effect of fatty acids and selected drugs on the albumin binding of a long-acting, acylated insulin analogue. J Pharm Sci 86(12):1365–1368
30. Langer K, Balthasar S, Vogel V, Dinauer N, von Briesen H, Schubert D (2003) Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int J Pharm 257(1–2):169–180
31. le Thao Q, Byeon HJ, Lee C, Lee S, Lee ES, Choi HG, Park ES, Youn YS (2016a) Pharmaceutical potential of tacrolimus–loaded albumin nanoparticles having targetability to rheumatoid arthritis tissues. Int J Pharm 497(1–2):268–276
32. le Thao Q, Byeon HJ, Lee C, Lee S, Lee ES, Choi YW, Choi HG, Park ES, Lee KC, Youn YS (2016b) Doxorubicin-bound albumin nanoparticles containing a TRAIL protein for targeted treatment of colon cancer. Pharm Res 33(3):615–626
33. Lee J, Lee C, Kim I, Moon HR, Kim TH, Oh KT, Lee ES, Lee KC, Youn YS (2012a) Preparation and evaluation of palmitic acid-conjugated exendin-4 with delayed absorption and prolonged circulation for longer hypoglycemia. Int J Pharm 424(1–2):50–57
34. Lee J, Lee C, Kim TH, Chi SC, Moon HR, Oh KT, Lee ES, Lee KC, Youn YS (2012b) Pulmonary administered palmitic–acid modified exendin-4 peptide prolongs hypoglycemia in type 2 diabetic db/db mice. Regul Pept 177(1–3):68–72
35. Léger R, Thibaudeau K, Robitaille M, Quraishi O, van Wyk P, Bousquet-Gagnon N, Carette J, Castaigne JP, Bridon DP (2004) Identification of CJC-1131-albumin bioconjugate as a stable and bioactive GLP-1(7-36) analog. Bioorg Med Chem Lett 14(17):4395–4398
36. Levick JR (1981) Permeability of rheumatoid and normal human synovium to specific plasma proteins. Arthritis Rheum 24(12):1550–1560
37. Li C, Li Y, Gao Y, Wei N, Zhao X, Wang C, Li Y, Xiu X, Cui J (2014) Direct comparison of two albumin–based paclitaxel–loaded nanoparticle formulations: is the crosslinked version more advantageous? Int J Pharm 468(1–2):15–25
38. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65(1–2):271–284
39. Markussen J, Havelund S, Kurtzhals P, Andersen AS, Halstrøm J, Hasselager E, Larsen UD, Ribel U, Schäffer L, Vad K, Jonassen I (1996) Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 39(3):281–288
40. Mendez CM, McClain CJ, Marsano LS (2005) Albumin therapy in clinical practice. Nutr Clin Pract 20(3):314–320
41. Michaelis K, Hoffmann MM, Dreis S, Herbert E, Alyautdin RN, Michaelis M, Kreuter J, Langer K (2006) Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain. J Pharmacol Exp Ther 317(3):1246–1253
42. Min SY, Byeon HJ, Lee C, Seo J, Lee ES, Shin BS, Choi HG, Lee KC, Youn YS (2015) Facile one-pot formulation of TRAIL-embedded paclitaxel-bound albumin nanoparticles for the treatment of pancreatic cancer. Int J Pharm 494(1):506–515
43. Moreno-Aspitia A, Perez EA (2005) Nanoparticle albumin-bound paclitaxel (ABI-007): a newer taxane alternative in breast cancer. Future Oncol 1(6):755–762
44. Podhajcer OL, Benedetti LG, Girotti MR, Prada F, Salvatierra E, Llera AS (2008) The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev 27(4):691–705
45. Sage H, Johnson C, Bornstein P (1984) Characterization of a novel serum albumin-binding glycoprotein secreted by endothelial cells in culture. J Biol Chem 259(6):3993–4007
46. Seo J, Lee C, Hwang HS, Kim B, le Thao Q, Lee ES, Oh KT, Lim JL, Choi HG, Youn YS (2016) Therapeutic advantage of inhaled tacrolimus-bound albumin nanoparticles in a bleomycin-induced pulmonary fibrosis mouse model. Pulm Pharmacol Ther 36:53–61
47. Singh KV, Kaur J, Varshney GC, Raje M, Suri CR (2004) Synthesis and characterization of hapten-protein conjugates for antibody production against small molecules. Bioconjug Chem 15(1):168–173
48. Sleep D (2015) Albumin and its application in drug delivery. Expert Opin Drug Deliv 12(5):793–812
49. Son S, Song S, Lee SJ, Min S, Kim SA, Yhee JY, Huh MS, Chan Kwon I, Jeong SY, Byun Y, Kim SH, Kim K (2013) Self-crosslinked human serum albumin nanocarriers for systemic delivery of polymerized siRNA to tumors. Biomaterials 34(37):9475–9485
50. Subramanian GM, Fiscella M, Lamousé-Smith A, Zeuzem S, McHutchison JG (2007) Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C. Nat Biotechnol 25(12):1411–1419
51. Wagner S, Rothweiler F, Anhorn MG, Sauer D, Riemann I, Weiss EC, Katsen-Globa A, Michaelis M, Cinatl J Jr, Schwartz D, Kreuter J, von Briesen H, Langer K (2010) Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin nanoparticles. Biomaterials 31(8):2388–2398
52. Weber C, Coester C, Kreuter J, Langer K (2000) Desolvation process and surface characterisation of protein nanoparticles. Int J Pharm 194(1):91–102
53. Wilkinson P, Jeremy R, Brooks FP, Hollander JL (1965) The mechanism of hypoalbuminemia in rheumatoid arthritis. Ann Intern Med 63:109–114
54. Wilson B, Lavanya Y, Priyadarshini SR, Ramasamy M, Jenita JL (2014) Albumin nanoparticles for the delivery of gabapentin: preparation, characterization and pharmacodynamic studies. Int J Pharm 473(1–2):73–79
55. Xu R, Fisher M, Juliano RL (2011) Targeted albumin-based nanoparticles for delivery of amphipathic drugs. Bioconjug Chem. 22(5):870–878
56. Yang Z, Gong W, Wang Z, Li B, Li M, Xie X, Zhang H, Yang Y, Li Z, Li Y, Yu F, Mei X (2015) A novel drug-polyethylene glycol liquid compound method to prepare 10-hydroxycamptothecin loaded human serum albumin nanoparticle. Int J Pharm 490(1–2):412–428
57. Yuan A, Wu J, Song C, Tang X, Qiao Q, Zhao L, Gong G, Hu Y (2013) A novel self-assembly albumin nanocarrier for reducing doxorubicin-mediated cardiotoxicity. J Pharm Sci 102(5):1626–1635
58. Zhang S, Kucharski C, Doschak MR, Sebald W, Uludağ H (2010) Polyethylenimine-PEG coated albumin nanoparticles for BMP-2 delivery. Biomaterials 31(5):952–963
59. Zhao L, Zhou Y, Gao Y, Ma S, Zhang C, Li J, Wang D, Li X, Li C, Liu Y, Li X (2015) Bovine serum albumin nanoparticles for delivery of tacrolimus to reduce its kidney uptake and functional nephrotoxicity. Int J Pharm 483(1–2):180–187
60. Zimmera AK, Zerbe H, Kreuter J (1994) Evaluation of pilocarpine-loaded albumin particles as drug delivery systems for controlled delivery in the eye I. In vitro and in vivo characterization. J Control Release 32(1):57–70